Jan Maarten V. H.
- Country
- The Netherlands
- Department
- Lung department
Research Overview
- A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiotherapy (SBRT) with or without Pembrolizumab (MK-3475) in Participants with Unresected Stage I or II Non-Small Cell Lung Cancer (NSCLC) (KEYNOTE-867)
- A Phase III Double-Blind, Placebo-Controlled Study of Adjuvant Durvalumab in Resected Stage IB-IIIA Non-Small Cell Lung Cancer with PD-L1 Expression ≥25%
- Evaluation of Pembrolizumab Monotherapy Versus Pembrolizumab Combined with Chemotherapy in First-Line Treatment of Advanced Stage Non-Small Cell Lung Cancer
Data & Insights
Has run more than one trial at 5 of 147 partner sites.
Specializations
Advanced Lung Cancer Management
This investigator specializes in treating advanced stage non-small cell lung cancer (NSCLC), with particular expertise in implementing innovative therapeutic approaches for patients with high tumor burden.
- PD-L1 Expression Analysis
- Immunotherapy Response Assessment
- Combined Treatment Strategies
Key focus on evaluating treatment outcomes in patients with specific biomarker profiles.
Early-Stage Lung Cancer Treatment
The investigator works extensively with resectable NSCLC, particularly focusing on post-surgical therapeutic interventions in stages IB through IIIA cases.
- Adjuvant Therapy Optimization
- Disease-Free Survival Assessment
- Biomarker-Driven Treatment Selection
Specialized interest in post-resection treatment strategies for improved patient outcomes.
Novel Treatment Approaches
Expertise in managing unresectable early-stage NSCLC through innovative treatment combinations, including stereotactic body radiation therapy (SBRT) approaches.
- Radiation Therapy Integration
- Event-Free Survival Analysis
- Non-Surgical Treatment Options
Focus on developing alternative treatment strategies for inoperable cases.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.